Orphazyme A/S
ORPH
ORPH was delisted on the 30th of March, 2022.
20 hedge funds and large institutions have $3.31M invested in Orphazyme A/S in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.
300% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $384K
9% less funds holding
Funds holding: 22 → 20 (-2)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
26% less capital invested
Capital invested by funds: $4.47M → $3.31M (-$1.16M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$576K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$535K |
| 3 |
PA
Profund Advisors
Bethesda,
Maryland
|
+$450K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$335K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$349K |
| 2 |
BAM
Blueshift Asset Management
Red Bank,
New Jersey
|
-$338K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$226K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$145K |
| 5 |
Millennium Management
New York
|
-$139K |
ORPH Hedge Fund Activity: Q4 2021 in Review
20 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Orphazyme A/S (ORPH) for Q4 2021, worth a combined $3.31M — down 26% from $4.47M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ORPH and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $576K. The largest seller was Two Sigma Investments, cutting an estimated $349K.
- 20 institutional investors held Orphazyme A/S (ORPH) as of Q4 2021, down from 22 in Q3 2021.
- Funds reported $3.31M of Orphazyme A/S stock for Q4 2021, down 26% quarter-over-quarter.
- 3 funds opened new Orphazyme A/S positions in Q4 2021 and 5 closed out, a net change of -2 holders.
- The largest Orphazyme A/S buyer in Q4 2021 was Renaissance Technologies, an estimated $576K added.
- The largest Orphazyme A/S seller in Q4 2021 was Two Sigma Investments, an estimated $349K sold.
Based on aggregated 13F filings for Q4 2021.